Gino Francesco, Chief Executive Officer at IMUCEL, shared on LinkedIn:
“A New Front Door To Access Cancer Diagnosis and Treatment
When the NHS was created in Great Britain in the 1950s, it was an extraordinary achievement-giving people access to healthcare regardless of income. It’s hard to overstate how much it changed lives.
Cancer care is a different challenge. Around 80 years ago, the science and tools needed to diagnose and treat cancer effectively largely didn’t exist, and widespread advances really began later. Over time, there has been remarkable progress in research, technology, and treatment. Yet one barrier has become more visible, being access to cancer services: too many people still face long delays in getting a diagnosis and starting treatment, and those delays can and do contribute to preventable deaths.
At the moment, the NHS healthcare system is stretched. Many demands compete for the same limited capacity, and even when referral pathways are in place, the most damaging failure is often the time it takes to move from first symptoms to a confirmed cancer diagnosis and then to treatment.
A possible solution would be to redesign cancer services access, so patients can reach diagnostic services quickly-without waiting behind non-cancer demand.
One model could be a privately run independent cancer ‘front door‘ providing faster access to diagnostic services, while treatment delivery remain supported through the NHS. Under such an approach, once a cancer is confirmed, a clear treatment plan using Al can be issued promptly and delivered without unnecessary delay. This model can be extended – where the Government has invested heavily in Al hubs that can contain historical cancer patient treatment records allowing Al therapy plans to be generated in seconds based on likely outcomes – and then able to improve individual treatments further, based on actual treatment responses, without any expert human involvement.
Reducing this access bottleneck-especially the time to diagnosis and first treatment-could do more to prevent cancer deaths than further adjustments that don’t address the core problem.
This is a wonderful opportunity for both private enterprise and cancer patients to both equally profit from, and at much less cost than if through the NHS.”
Other articles about AI in oncology on OncoDaily.